Jiangsu Sihuan Bioengineering Co., Ltd (SHE:000518)
2.740
+0.020 (0.74%)
Jan 23, 2026, 3:04 PM CST
SHE:000518 Revenue
Jiangsu Sihuan Bioengineering had revenue of 112.48M CNY in the quarter ending September 30, 2025, with 124.12% growth. This brings the company's revenue in the last twelve months to 341.90M, up 61.67% year-over-year. In the year 2024, Jiangsu Sihuan Bioengineering had annual revenue of 203.52M, down -13.55%.
Revenue (ttm)
341.90M
Revenue Growth
+61.67%
P/S Ratio
8.19
Revenue / Employee
1.23M
Employees
277
Market Cap
2.80B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 203.52M | -31.90M | -13.55% |
| Dec 31, 2023 | 235.42M | -34.73M | -12.86% |
| Jan 1, 2023 | 270.15M | -80.81M | -23.03% |
| Jan 1, 2022 | 350.96M | -154.44M | -30.56% |
| Dec 31, 2020 | 505.40M | 87.52M | 20.94% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Universal Biotech | 1.07B |
| Shandong Sito Bio-technology | 954.76M |
| Guiyang Xintian Pharmaceutical | 755.34M |
| Jilin Jian Yisheng Pharmaceutical | 639.10M |
| Hubei Goto Biopharm | 626.28M |
| Sailong Pharmaceutical Group | 244.84M |
| Shanghai Serum Bio-Technology | 196.76M |
| Jiangsu CoWin Biotech | 167.17M |